Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.
GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.
Wacker Chemie, a chemical company based in Munich, purchased a Dutch biopharma manufacturing site from SynCo Bio Luxembourg for an undisclosed price.
The FDA made public a voluntary recall of sterile injectables made by Coastal Meds of Mississippi, after visible particles were found in some vials.
It’s been a strange road for BMS' Opdivo-Yervoy combo in first-line kidney cancer, but the New Jersey drugmaker finally has a go-ahead.
The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.
Merck's Gardasil 9 has been on an upward trajectory, but high global demand for the HPV shot has created a shortage for U.K. private clinics.
At €350 million, Sanofi's new Canadian vaccine plant will be one of the largest investments ever by the company in a single facility.
The FDA hit New Jersey-based CMO Tris Pharma with a warning letter, citing significant violations.
Spurred by U.S. tax breaks, Amgen will build a $165 million next-generation biologics plant in West Greenwich, Rhode Island.